Autres langues VALBIOTIS

Actions

ALVAL

FR0013254851

Marché Fermé - Euronext Paris Autres places de cotation 17:26:37 25/04/2024			Varia. 5j.	Varia. 1 janv.
3,965 ^EUR	+0,89 %		+2,06 %	-20,70 %

03/04	Valbiotis : lancement en mai de Valbiotis PRO Cholestérol	CF
03/04	Après Pâques, un truc qui cloche

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Valbiotis : lancement en mai de Valbiotis PRO Cholestérol	03/04
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May	03/04
Valbiotis presents its 2024 financial communication calendar	29/01
Valbiotis sets out its commercial and clinical roadmap for 2024	16/01
Valbiotis : l'augmentation de capital bouclée avec succès	22/12
Valbiotis announces the success of its €15 M capital increase	22/12
Actualización de las fuertes variaciones del día: Adquisición de tecnología en Suecia y otras	12/12
Valbiotis : augmentation de capital de 15 ME	12/12
Valbiotis' Plant Extract Receives New Dietary Ingredient Status from US FDA	12/12
Valbiotis announces the launch of a capital increase	11/12
Valbiotis announces the availability of an amendment to the Universal Registration Document	11/12
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status	11/12
VALBIOTIS SA:	04/12
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes	07/11
VALBIOTIS : Rapport financier semestriel 2023	15/10/23
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes	02/10/23
Valbiotis SA Reports Earnings Results for the Half Year Ended June 30, 2023	28/09/23
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap	28/09/23
Valbiotis presents the full results of the Phase II/III REVERSE-IT study, impressive efficacy of TOTUM 63 against prediabetes and the early stages of type 2 Diabetes, a first for a non-drug active substance	12/09/23
Valbiotis : le titre grimpe, succès d'une étude clinique	12/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues VALBIOTIS

Actions

ALVAL

FR0013254851

Autres langues

Filtres